AstraZeneca has entered a global collaboration and license agreement with CSPC Pharmaceutical Group, securing exclusive ex-China rights to the latter’s once‑monthly injectable weight‑management portfolio. The deal, which is valued at up to a staggering US$18.5 B, is driven by key assets such as SYH2082, a Phase I long‑acting GLP‑1/GIP agonist as well as three preclinical programmes leveraging CSPC’s LiquidGel extended‑release platform. As competition intensifies, this partnership helps to strengthen AstraZeneca’s position in the lucrative obesity market by developing alternative, long‑acting treatments.